ArticleCureus2026
Effects of Hydroxytyrosol Against Doxorubicin-Induced Hepatotoxicity Through Alterations in Dardarin and Podocalyxin Expression in Rats.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study investigated whether dardarin (LRRK2) and podocalyxin (PODX) contribute to the hepatoprotective effects of hydroxytyrosol (HT) against doxorubicin (DOX)-induced liver injury in rats.
methodsTwenty-eight female Sprague Dawley rats were randomly assigned to four groups: Control, HT, DOX, and DOX+HT. DOX (10 mg/kg) was administered intraperitoneally as a single dose on day 1. HT was given orally at 100 mg/kg/day for 28 days. In the DOX+HT group, animals received DOX on day 1 followed by daily oral HT for 28 days. At the end of the experiment, liver tissues were collected for histopathological evaluation, and all findings were statistically analyzed.
resultsHistopathological assessments showed significantly elevated LRRK2 and PODX expression levels in the DOX group, while co-treatment with HT markedly reduced these increases (p<0.001). Additionally, DOX-induced hepatic fibrosis, leukocyte infiltration, congestion, and sinusoidal dilatation were substantially alleviated in the DOX+HT group (p<0.001).
conclusionHT demonstrated beneficial effects on histopathological and immunohistochemical changes in DOX-induced liver injury. The reduction in LRRK2 and PODX expression implies that these molecules may be involved in the mechanisms underlying HT-mediated hepatoprotection. These findings highlight the potential therapeutic value of HT in mitigating DOX-associated hepatotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.